Biogen's EU setback highlights importance of research, says Alzheimer's organization
![Nis Peter Nissen, head of Danish non-profit organization Alzheimerforeningen | Photo: Mathias Christensen/Politiken/Ritzau Scanpix](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13484076.ece/ALTERNATES/schema-16_9/20100820-142855-pf-1920x1079we.jpg)
Although the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) giving the company's Alzheimer's drug Aduhelm (aducanumab) the thumbs-down in a trend vote on Wednesday was a spanner in the works for Biogen, there might still be a silver lining for the company.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Biogen passes FDA test for Alzheimer's medicine
For subscribers
Biogen's Alzheimer's drug Aduhelm faces EU rejection
For subscribers